Engaging with healthcare professionals
In all of our interactions with healthcare professionals, our priority is to be transparent about our work, operate with integrity, and always put the interests of patients first.
As a healthcare company, we regularly work with healthcare professionals. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
In October 2018, we announced a series of changes to our policy for how we work with healthcare professionals (HCPs). The purpose of these changes is to improve understanding of new data and clinical experience with our products and increase transparency of payments to HCPs. The changes will apply to innovative products for a limited time and aim to support HCPs to deliver better outcomes for patients.
We are making the following changes to our policy to help improve sharing of new data on our products among HCPs. Going forward, GSK in Canada will:
- Make fair market value payments to global expert practitioners who speak about the new science behind selected GSK products, their associated diseases and clinical practice in non-promotional settings.
- As per Innovative Medicines Canada (IMC) code, GSK in Canada will continue to not sponsor HCPs to attend local conferences nor pay HCPs to attend remote congress and webinars.
To reach more information about this policy, please visit our global website link (English only).
We believe that transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines, improve clinical practice and care for patients. These are the principles that underpin our policy of engagement with HCPs and we remain fully committed to them.
We are committed to publicly disclosing payments we do make to healthcare professionals. Find out more about our transparency disclosures here.